Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Pharma
Asia
Drug Delivery
Executives
Clinical Data
Vaccines
Special Reports
Trending
COVID-19
Cell & Gene Therapy
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Vyvanse
Pharma
Takeda braces for Vyvanse's blockbuster patent loss
Vyvanse grew sales by 20.4% to $2.52 billion in Takeda's fiscal year 2021 and is expected to face generic entry in August 2023.
Angus Liu
May 11, 2022 10:25am
Takeda, Celltrion, BMS-Dr. Reddy's and more—FiercePharmaAsia
Sep 18, 2020 9:55am
Takeda targets adult ADHD patients in 'V is for Vyvanse' ads
Sep 17, 2020 4:37pm
Shire launches ADHD med Mydayis as it weighs a neuroscience exit
Aug 28, 2017 10:15am
Shire looks for more ADHD mileage with new data on long-acting prospect
Jul 5, 2016 3:56pm
With weight-control peers flailing, Shire keeps growing Vyvanse
May 11, 2016 9:59am
